Lyell Immunopharma (LYEL) Operating Income (2020 - 2026)
Lyell Immunopharma (LYEL) reported Operating Income of -$44.3 million for Q1 2026, up 22.85% on a YoY basis from -$36.0 million in Q1 2025, and up 65.32% sequentially from -$127.6 million in Q4 2025.
Lyell Immunopharma (LYEL) Operating Income (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Operating Income data on file, last reported at -$44.3 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 22.85% year-over-year to -$44.3 million; the trailing twelve-month figure through Mar 2026 stood at -$256.3 million (up 28.91% YoY), and the FY2025 full-year result was -$269.4 million, up 24.91% from the prior year.
- Operating Income advanced to -$44.3 million in Q1 2026, from -$127.6 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$14.8 million in Q4 2022 to a low of -$201.1 million in Q4 2024.
- A 5-year average of -$65.1 million and a median of -$57.4 million in 2025 frame the typical range for Operating Income.
- Across the five-year window, Operating Income jumped 68.9% in 2022 and slumped 302.52% in 2023, its largest moves.
- Tracing LYEL's Operating Income over 5 years: stood at -$14.8 million in 2022, then tumbled by 302.52% to -$59.5 million in 2023, then sank by 238.02% to -$201.1 million in 2024, then soared by 36.54% to -$127.6 million in 2025, then surged by 65.32% to -$44.3 million in 2026.
- Business Quant data shows LYEL's Operating Income at -$44.3 million in Q1 2026, -$127.6 million in Q4 2025, and -$37.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | -44.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.26 Mn |
| Dec 31, 2025 | -127.64 Mn |
| Sep 30, 2025 | -37.25 Mn |
| Jun 30, 2025 | -47.14 Mn |
| Mar 31, 2025 | -57.37 Mn |
| Dec 31, 2024 | -201.15 Mn |
| Sep 30, 2024 | -50.51 Mn |
| Jun 30, 2024 | -51.53 Mn |
| Mar 31, 2024 | -55.58 Mn |
| Dec 31, 2023 | -59.51 Mn |
| Sep 30, 2023 | -59.04 Mn |
| Jun 30, 2023 | -65.91 Mn |
| Mar 31, 2023 | -62.56 Mn |
| Dec 31, 2022 | -14.78 Mn |
| Sep 30, 2022 | -66.44 Mn |
| Jun 30, 2022 | -37.26 Mn |
| Mar 31, 2022 | -68.58 Mn |
| Dec 31, 2021 | -47.54 Mn |
| Sep 30, 2021 | -49.16 Mn |
| Jun 30, 2021 | -62.71 Mn |